•		ms Branch	1600
Serial I	lumber: 09,902,556 A	CRF Processing I	Date: 1/25/2002
	Changed a file from non-ASCII to ASCII	Verified by:	(SIII) sta
	Changed the margins in cases where the sequence text was Wrapped	d" down to the ne:	A SECTION
	Edited a format error in the Current Application Data section, specifica	dly:	2 2
	Edited the Current Application Data section with the actual current numapplicant was the prior application data; or other	mber. The numbe	or in the d by
	Added the mandatory heading and subheadings for "Current Application	on Data".	171
	Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.		
	Changed the spelling of a mandatory field (the headings or subheadings), specifically:		
	Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:		
	Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:		
	Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.		
	Inserted colons after headings/subheadings. Headings edited include	d: 	
	Deleted extra, invalid, headings used by an applicant, specifically:		·
	Deleted: ☐ non-ASCII "garbage" at the beginning/end of files; ☐ s ☐ page numbers throughout text; ☐ other invalid text, such as	secretary initials/fil	ename at end of file
	Inserted mandatory headings, specifically:		
	Corrected an obvious error in the response, specifically:		· 
	Edited identifiers where upper case is used but lower case is required	l, or vice versa.	
	Corrected an error in the Number of Sequences field, specifically:		
	A "Hard Page Break" code was inserted by the applicant. All occurrer	nces had to be de	leted.
	Deleted <i>ending</i> stop codon in amino acid sequences and adjusted the due to a Patentin bug). Sequences corrected:		
	Other: Seg 2-conected misabgred arend a	eid nos.	

\*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.



RAW SEQUENCE LISTING

1 <110> APPLICANT: Deghenghi, Romano

PATENT APPLICATION: US/09/902,556A

Input Set : N:\Crf3\07252002\I902556.raw
Output Set: N:\CRF4\08052002\I902556A.raw

```
2 <120> TITLE OF INVENTION: GHRELIN ANTAGONISTS
      3 <130> FILE REFERENCE: 87264-200
      4 <140> CURRENT APPLICATION NUMBER: US/09/902,556A
C--> 5 <141> CURRENT FILING DATE: 2002-07-10
      6 <150> PRIOR APPLICATION NUMBER: US 60/220,178
      7 <151> PRIOR FILING DATE: 2000-07-13
      8 <160> NUMBER OF SEQ ID NOS: 5
      9 <170> SOFTWARE: PatentIn version 3.1
     11 <210> SEQ ID NO: 1
     12 <211> LENGTH: 8
     13 <212> TYPE: PRT
     14 <213> ORGANISM: Artificial Sequence
     15 <220> FEATURE:
     16 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of
known Ghrelin
     17
              peptides which were isolated in the stomach by a distinct cell type in rats and
     18
              humans.
     19 <220> FEATURE:
     20 <221> NAME/KEY: MOD_RES
     21 <222> LOCATION: (3)..(3)
     22 <223> OTHER INFORMATION: Octanoyl ester attached to serine residue
     23 <400> SEQUENCE: 1
              Gly Ser Ser Phe Leu Ser Pro Glu
     24
     25
              1
     27 <210> SEQ ID NO: 2
     28 <211> LENGTH: 10
     29 <212> TYPE: PRT
     30 <213> ORGANISM: Artificial Sequence
     31 <220> FEATURE:
     32 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of
known Ghrelin
              peptides which were isolated in the stomach by a distinct cell type in rats and
     33
     34
              humans.
     35 <220> FEATURE:
     36 <221> NAME/KEY: MOD_RES
     37 <222> LOCATION: (3)..(3)
     38 <223> OTHER INFORMATION: Octanoyl ester attached to serine residue
     39 <400> SEQUENCE: 2
     40
              Gly Ser Ser Phe Ala Lys Leu Gln Pro Arg
     41
              1
     43 <210> SEQ ID NO: 3
```


44 <211> LENGTH: 8 45 <212> TYPE: PRT 46 <213> ORGANISM: Artificial Sequence

RAW SEQUENCE LÍSTING DATE: 08/05/2002 PATENT APPLICATION: US/09/902,556A TIME: 15:34:23

Input Set : N:\Crf3\07252002\1902556.raw
Output Set: N:\CRF4\08052002\1902556A.raw

```
47 <220> FEATURE:
     48 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of
known Ghrelin
              peptides which were isolated in the stomach by a distinct cell type in rats and
     49
     50
              humans.
     51 <220> FEATURE:
     52 <221> NAME/KEY: MOD_RES
     53 <222> LOCATION: (3)..(3)
     54 <223> OTHER INFORMATION: An octanoyl ester is attached to the serine residue
     55 <400> SEQUENCE: 3
              Gly Ser Ser Phe Leu Ser Pro Glu
     56
     57
              1
     59 <210> SEQ ID NO: 4
     60 <211> LENGTH: 14
     61 <212> TYPE: PRT
     62 <213> ORGANISM: Artificial Sequence
     63 <220> FEATURE:
     64 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of
known Ghrelin
              peptides which were isolated in the stomach by a distinct cell type in rats and
     65
              humans.
     67 <220> FEATURE:
     68 <221> NAME/KEY: MOD_RES
     69 <222> LOCATION: (3)..(3)
     70 <223> OTHER INFORMATION: An octanoyl ester is attached to the serine residue
     71 <400> SEQUENCE: 4
     72
              Gly Ser Ser Phe Leu Ser Pro Glu Ala Lys Leu Gln Pro Arg
     73
                              5
     75 <210> SEQ ID NO: 5
     76 <211> LENGTH: 4
     77 <212> TYPE: PRT
     78 <213> ORGANISM: Artificial Sequence
     79 <220> FEATURE:
     80 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of
known Ghrelin
              peptides which were isolated in the stomach by a distinct cell type in rats and
     81
     82
              humans.
     83 <220> FEATURE:
     84 <221> NAME/KEY: MOD_RES
     85 <222> LOCATION: (3)..(3)
     86 <223> OTHER INFORMATION: An octanoyl ester is attached to the serine residue
     87 <400> SEQUENCE: 5
     88
              Gly Ser Ser Phe
```

89



DATE: 08/05/2002 TIME: 15:34:24

Input Set : N:\Crf3\07252002\I902556.raw
Output Set: N:\CRF4\08052002\I902556A.raw

## Invalid Line Length:

The rules require that a line not exceed 72 characters in length. This includes spaces.

Seq#:1; Line(s) 16,17 Seq#:2; Line(s) 32,33 Seq#:3; Line(s) 48,49 Seq#:4; Line(s) 64,65 Seq#:5; Line(s) 80,81



1646

RAW SEQUENCE LISTING

DATE: 07/24/2002

**Does Not Comply** 

Corrected Diskette Needed

PATENT APPLICATION: US/09/902,556A

TIME: 12:26:01

Input Set : A:\pto\_vsk.txt

Output Set: N:\CRF3\07242002\I902556.raw

- 3 <110> APPLICANT: Deghenghi, Romano
- 5 <120> TITLE OF INVENTION: GHRELIN ANTAGONISTS
- 7 <130> FILE REFERENCE: 87264-200
- 9 <140> CURRENT APPLICATION NUMBER: US 09/902,556
- 10 <141> CURRENT FILING DATE: 2001-07-10
- 12 <150> PRIOR APPLICATION NUMBER: US 60/220,178
- 13 <151> PRIOR FILING DATE: 2000-07-13
- 15 <160> NUMBER OF SEQ ID NOS: 5
- 17 <170> SOFTWARE: PatentIn version 3.1

## ERRORED SEQUENCES

- 39 <210> SEQ ID NO: 2
- 40 <211> LENGTH: 10
- 41 <212> TYPE: PRT
- 42 <213> ORGANISM: Artificial Sequence
- 44 <220> FEATURE:
- 45 <223> OTHER INFORMATION: An Artificial Sequence which is a synthetic variation of known Ghrelin
  - 46 peptides which were isolated in the stomach by a distinct cell type in rats and
    - 47 humans.
    - 49 <220> FEATURE:
    - 50 <221> NAME/KEY: MOD\_RES
    - 51 <222> LOCATION: (3)..(3)
    - 52 <223> OTHER INFORMATION: Octanoyl ester attached to serine residue
    - 54 <400> SEQUENCE: 2
    - 56 Gly Ser Ser Phe Ala Lys Leu Gln Pro Arg
- E--> 57 1

5 <del>110</del>--

10 misalgred nos

7/24/02

· VERIFICATION SUMMARY

PATENT APPLICATION: US/09/902,556₽

DATE: 07/24/2002

TIME: 12:26:02

Input Set : A:\pto\_vsk.txt

Output Set: N:\CRF3\07242002\I902556.raw

L:57 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:2